Core Insights - Precipio, Inc. has reported strong preliminary financial results for Q4-2025 and fiscal year 2025, highlighting significant growth in revenue and positive cash flow metrics [1][5]. Financial Performance - Revenue Growth: Precipio's revenues increased from $18.5 million in 2024 to $24.0 million in 2025, representing a 30% year-over-year increase. Q4-2025 revenues were $6.7 million, up 23% from $5.4 million in Q4-2024 [5]. - Positive Adjusted EBITDA: The company will report Adjusted EBITDA of $0.95 million for Q4-2025 and $1.23 million for the full year 2025, compared to $0.40 million in Q4-2024 and a loss of $1.5 million for the full year 2024 [5]. - Positive Operating Cash Flow: Precipio will report $368,000 of positive operating cash flow during Q4-2025 and a total of $688,000 for 2025, compared to $439,000 generated from operations in 2024 [5]. Management Commentary - The CEO, Ilan Danieli, emphasized the importance of becoming an EBITDA and cash-flow positive business, allowing for investments in long-term growth projects rather than focusing solely on short-term cash burn [2]. The company experienced a strong performance in 2025, with shareholders seeing their value triple [2]. Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services that enhance accuracy and improve patient outcomes [6].

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics [Accessibility Statement] Skip NavigationAt AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutionsSAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to combine mor ...

Source: BenzingaBut beneath the surface, a powerful positioning imbalance is quietly building.40% Short Interest Creates A Structural Pressure PointMore than 135 million ImmunityBio shares are currently sold short, representing over 40% of its float. That's an unusually high level — and one that creates structural risk for bearish investors if the stock continues rising.Short sellers eventually must buy back shares to close positions. When prices rise rapidly, that process can accelerate, forcing additional ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBen Taylor - CFO and President of Recursion UKDave Hallett - Chief Scientific OfficerNajat Khan - CEO and PresidentNajat KhanGood morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of l ...

Geron (NasdaqGS:GERN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAhmed ElNawawi - EVP and Chief Commercial OfficerCorinne Johnson - Managing DirectorDawn Schottlandt - Senior VP, Investor Relations, and Corporate AffairsHarout Semerjian - President and CEOJoseph Eid - EVP of Research and DevelopmentMichelle Robertson - EVP, CFO and, TreasurerConference Call ParticipantsEmily Bodnar - Biotech Equity Research AnalystGil Blum - Senior Biotech AnalystStephen Willey - Managing Direct ...

Turn Therapeutics (NasdaqGM:TTRX) FY Conference February 25, 2026 08:00 AM ET Company ParticipantsBradley Burnam - Founder and CEOBradley BurnamI'm going to just start us off here. I'm gonna thank Oppenheimer for inviting us to Turn. I'm going to thank Leland for introducing us, hearing himself again, I'm sure on echo was interesting, and I'm sure he'll be back on to moderate. Joining me is Zuraiz Chaudhary, our CFO, arguably one of the most brilliant financial experts I know, I'm Bradley Burnam, CEO, Found ...

Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBahija Jallal - CEOGraig Suvannavejh - Managing DirectorMohammed Dar - EVP of Clinical Development and Chief Medical OfficerMorgan Morse - Investor Relations ManagerPaul Jeng - VP of Biotechnology Equity ResearchRajan Sharma - Pharma and Biotech Equity ResearchRalph Torbay - EVP of CommercialSean Laaman - Executive DirectorTravis Coy - CFO and Head of Corporate DevelopmentConference Call ParticipantsEric Schmi ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker2Good morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of large-scale biological data generation, machine learning, and compute to better understand the complexity of biology. We have also deliber ...

Geron (NasdaqGS:GERN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker8Please be advised that today's conference is being recorded. I would now like to turn the call over to Dawn Schottlandt, Senior Vice President, Investor Relations and Corporate Affairs. You may begin.Speaker2Good morning, everyone. Welcome to the Geron Corporation fourth quarter 2025 earnings conference call. Before we begin, please note that during the course of this presentation and question and answer session, we will be ma ...

NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit. ...